Research programme: RNA interference-based inflammation therapeutics - Marina Biotech

Drug Profile

Research programme: RNA interference-based inflammation therapeutics - Marina Biotech

Alternative Names: MDR-06155

Latest Information Update: 24 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action Cytokine inhibitors; RNA interference; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 22 Jul 2010 Discontinued - Preclinical for Inflammatory bowel disease in USA (Parenteral)
  • 22 Jul 2010 Discontinued - Preclinical for Rheumatoid arthritis in USA (Parenteral)
  • 02 Jul 2010 MDRNA merged with Cequent Pharmaceuticals forming Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top